One of the biggest challenges in international development is anticipating when the next pandemic health threat will strike and how we can minimize its damage. Pandemics can be unpredictable, and it is hard to know when and where to focus attention. Having safe, effective drugs ready to use when they are needed saves lives. Clinical trials, which focus on safety and efficacy, are pivotal to the development of these drugs.
The full version of this post originally appeared on R&E Search for Evidence. Reposted with permission.
The U.S. President’s Emergency Plan for AIDS Relief (PEPFAR) is a remarkable success story built on the effective use of data. The achievements of this landmark initiative have played a central role in getting us to the point where we can finally talk about controlling the HIV epidemic and creating an AIDS-free generation.
Through 2016, US$70 billion has been invested in this unprecedented disease control effort. The accomplishments to date have been extraordinary and unimaginable just a few years ago: In 2016 alone, 74 million people were tested for HIV infection; since the start of PEPFAR, 2 million babies were born HIV-free due to women receiving prevention of mother-to-child HIV transmission (PMTCT) treatment; 12 million voluntary medical male circumcisions have been performed; and PEPFAR accounted for 12 million of the 18 million people globally receiving life-extending antiretroviral therapy (ART).